Research Analysts Issue Forecasts for SXTP Q4 Earnings

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Equities research analysts at HC Wainwright lowered their Q4 2024 earnings per share estimates for shares of 60 Degrees Pharmaceuticals in a research note issued to investors on Tuesday, February 25th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($4.77) for the quarter, down from their prior estimate of ($4.75). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ FY2025 earnings at ($3.59) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, February 19th.

60 Degrees Pharmaceuticals Trading Down 6.5 %

Shares of SXTP stock opened at $1.88 on Thursday. The company has a market cap of $2.77 million, a PE ratio of -0.19 and a beta of 4.22. The company’s fifty day simple moving average is $4.41 and its 200-day simple moving average is $5.52. 60 Degrees Pharmaceuticals has a 52 week low of $1.78 and a 52 week high of $35.99.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow bought 7,164 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was acquired at an average cost of $6.35 per share, for a total transaction of $45,491.40. Following the completion of the purchase, the chief executive officer now owns 18,916 shares of the company’s stock, valued at $120,116.60. This trade represents a 60.96 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 12,073 shares of company stock valued at $76,966 over the last 90 days. 10.27% of the stock is owned by corporate insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.